Back
 IJCM  Vol.9 No.5 , May 2018
Iron Indices and Mortality in Maintenance Hemodialysis Patients
Abstract: Background: The relationship between the iron indices and mortality in maintenance hemodialysis (MHD) patients has remained unclear. We performed a retrospective, observational cohort study to investigate the relationships between serum ferritin levels and mortality in MHD patients. Methods: MHD outpatients (n = 150) were followed up for a median period of 49 months. Their ESA and low-dose iron supplement dosages were adjusted to maintain their hemoglobin (Hb) concentrations in the 10 - 11 g/dl range in accordance with Japanese guidelines. The Kaplan-Meier method, log-rank tests, and Cox proportional hazards models were used to perform the statistical analyses. The patients were divided into 3 groups according to their serum ferritin levels: a serum ferritin < 50 ng/ml group; a 50 - 100 ng/ml group; and a > 100 ng/ml group. Results: During the median follow-up period of 49 months, there were 55 deaths. The multivariate analysis showed no significant associations between the ferritin level groups and all-cause mortality or cardiovascular (CV) events, and the Kaplan-Meier analysis showed no significant differences among the 3 ferritin level groups in all-cause mortality and CV event rates. However, the multivariate analysis revealed that age, CRP level and a history of previous CV disease were independently associated with all-cause mortality, while diabetes, previous CV disease, and iron administration were independently associated with CV events. Conclusion: The results of this study revealed no significant associations of MHD patients between the ferritin ranges and all-cause mortality or CV events. Thus, the adverse clinical outcomes in these patients were independently associated with other markers and not with their serum ferritin levels.
Cite this paper: Kumon, S. , Tanaka, Y. , Kimura, K. , Onuki, T. , Otsubo, S. and Nitta, K. (2018) Iron Indices and Mortality in Maintenance Hemodialysis Patients. International Journal of Clinical Medicine, 9, 454-466. doi: 10.4236/ijcm.2018.95039.
References

[1]   Masakane, I., Taniguchi, M.., Nakai, S., Tsuchida, K., Goto, S., Wada, A., Ogata, S., Hasegawa, T., Hamano, T., Hanafusa, N., Hoshino, J., Minakuchi, J. and Nakamoto, H. (2018) Annual Dialysis Data Report 2015, JSDT Renal Data Registry (JRDR). Renal Replacement Therapy, 4, 19.

[2]   Pisoni, R.L., Bragg-Gresham, J.L., Young, E.W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J.M., Kerr, P.G., Mendelssohn, D.C., Held, P.J. and Port, F.K. (2004) Anemia Management and Outcomes from 12 Countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 44, 94-111.
https://doi.org/10.1053/j.ajkd.2004.03.023

[3]   Nakanishi, T., Hasuike, Y., Otaki, Y., Nanami, M. and Kuragano, T. (2015) Dysregulated Iron Metabolism in Patients on Hemodialysis. Contribution to Nephrology, 185, 22-31.

[4]   Yamamoto, H., Nishi, S., Tomo, T., Masakane, I., Saito, K., Nangaku, M., Hattori, M., Suzuki, T., Morita, S., Ashida, A., Ito, Y., Kuragano, T., Komatsu, Y., Sakai, K., Tsubakihara, Y., Tsuruya K., Hayashi, T., Hirakata, H. and Honda, H. (2017) 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Renal Replacement Therapy, 3, 36.
https://doi.org/10.1186/s41100-017-0114-y

[5]   Madore, F., White, C.T., Foley, R.N., Barrett, B.J., Moist, L.M., Klarenbach, S.W., Culleton, B.F., Tonelli, M., Manns, B.J., Canadian Society of Nephrology. (2008) Clinical Practice Guidelines for Assessment and Management of Iron Deficiency. Kidney International Supplement, 110, S7-S11.
https://doi.org/10.1038/ki.2008.269

[6]   Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney International Supplement, 2, 279-335.

[7]   Kliger, A.S., Foley, R.N., Goldfarb, D.S., Goldstein, S.L., Johansen, K., Singh, A. and Szczech, L. (2013) KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. American Journal of Kidney Diseases, 62, 849-859.
https://doi.org/10.1053/j.ajkd.2013.06.008

[8]   Macginley, R., Walker, R. and Irving, M. (2013) KHA-CARI Guideline: Use of Iron in Chronic Kidney Disease Patients. Nephrology (Carlton), 18, 747-749.
https://doi.org/10.1111/nep.12139

[9]   Locatelli, F., Barany, P., Covic, A., De Francisco, L., Goldsmith, D., Horl, W., London, G., Vanholder, R., Van Biesen, W., ERA-EDTA ERBP Advisory Board. (2013) Kidney Disease: Improving Global Outcomes Guidelines on Anaemia Management in Chronic Kidney Disease: A European Renal Best Practice Position Statement. Nephrology Dialysis Transplantation, 28, 1346-1359.
https://doi.org/10.1093/ndt/gft033

[10]   Karaboyas, A., Zee, J., Morgenstern, H., Nolen, J.G., Hakim, R., Kalantar-Zadeh, K., Zager, P., Pisoni, R.L., Port, F.K. and Robinson, B.M. (2015) Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing. Clinical Journal of American Society of Nephrology, 10, 1814-1821.
https://doi.org/10.2215/CJN.02600315

[11]   Kuragano, T., Matsumura, O., Matsuda, A., Hara, T., Kiyomoto, H., Murata, T., Kitamura, K., Fujimoto, S., Hase, H., Joki, N., Fukatsu, A., Inoue, T., Itakura I. and Nakanishi, T. (2014) Association between Hemoglobin Variability, Ferritin Levels, and Adverse Events/Mortality in Maintenance Hemodialysis Patients. Kidney International, 86, 845-854.
https://doi.org/10.1038/ki.2014.114

[12]   Park, K.S., Ryu, G.W., Jhee, J.H., Kim, H.W., Park, S., Lee, S.A., Kwon, Y.E., Kim, Y.L., Ryu, H.J., Lee, M.J., Han, S.H., Yoo, T.H., Kim, Y.L., Kim, Y.S., Yang, C.W., Kim, N.H., Kang, S.W. and Park, J.T. (2015) Serum Ferritin Predicts Mortality Regardless of Inflammatory and Nutritional Status in Patients Starting Dialysis: A Prospective Cohort Study. Blood Purification, 40, 209-217.
https://doi.org/10.1159/000438819

[13]   Kawaguchi, T., Tong, L., Robinson, B.M., Sen, A., Fukuhara, S., Kurokawa, K., Canaud, B., Lamiere, N., Port, F.K. and Pisoni, R.L. (2011) C-Reactive Protein and Mortality in Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clinical Practice, 117, c167-c178.
https://doi.org/10.1159/000320116

[14]   Alberti, K.G. and Zimmet, P.Z. (1998) Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation. Diabetic Medicine, 15, 539-553.
https://doi.org/10.1002/(SICI)1096-9136(199807)15:7%3C539::AID-DIA668%3E3.0.CO;2-S

[15]   Tsubakihara, Y., Nishi, S., Akiba, T., Hirakata, H., Iseki, K., Kubota, M., Kuriyama, S., Komatsu, Y., Suzuki, M., Nakai, S., Hattori, M., Babazono, T., Hiramatsu, M., Yamamoto, H., Bessho, M. and Akizawa, T. (2010) 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Therapeutic Apheresis and Dialysis, 14, 240-275.
https://doi.org/10.1111/j.1744-9987.2010.00836.x

[16]   Saito, A., Onuki, T., Echida, Y., Otsubo, S. and Nitta, K. (2014) Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Hemodialysis Patients. International Journal of Clinical Medicine, 5, 1102-1110.
https://doi.org/10.4236/ijcm.2014.517141

[17]   Otterstad, J.E., Froeland, G., St John Sutton, M. and Holme, I. (1997) Accuracy and Reproducibility of Biplane Two-Dimensional Echocardiographic Measurements of Left Ventricular Dimensions and Function. European Heart Journal, 18, 507-513.
https://doi.org/10.1093/oxfordjournals.eurheartj.a015273

[18]   Hasuike, Y., Nonoguchi, H., Tokuyama, M., Ohue, M., Nagai, T., Yahiro, M., Nanami, M., Otaki, Y. and Nakanishi, T. (2010) Serum Ferritin Predicts Prognosis in Hemodialysis Patients: The Nishinomiya Study. Clinical and Experimental Nephrology, 14, 349-355.
https://doi.org/10.1007/s10157-010-0288-x

[19]   Shoji, T., Niihara, K., Fukuma, S., Fukuhara, S., Akizawa, T. and Inaba, M. (2017) Both Low and High Serum Ferritin Levels Predict Mortality Risk in Hemodialysis Patients without Inflammation. Clinical and Experimental Nephrology, 21, 685-693.
https://doi.org/10.1007/s10157-016-1317-1

[20]   Ogawa, C., Tsuchiya, K., Kanda, F. and Maeda, T. (2014) Low Levels of Serum Ferritin Lead to Adequate Hemoglobin Levels and Good Survival in Hemodialysis Patients. American Journal of Nephrology, 40, 561-570.
https://doi.org/10.1159/000370317

[21]   Wish, J.B. (2006) Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation. Clinical Journal of American Society of Nephrology, Suppl 1, S4-S8.
https://doi.org/10.2215/CJN.01490506

[22]   Ma, L. and Zhao, S. (2017) Risk Factors for Mortality in Patients Undergoing Hemodialysis: A Systematic Review and Meta-Analysis. International Journal of Cardiology, 238, 151-158.
https://doi.org/10.1016/j.ijcard.2017.02.095

 
 
Top